Better Health for All

CNS Pharmaceuticals, Inc. is a biopharmaceutical company focused entirely on developing novel therapies for severe, life-threatening cancers and neurological disorders, indicating a strong positive health impact. Its lead drug candidate, TPI 287, has been tested in over 350 patients and, in a 24-patient study for recurrent glioblastoma, demonstrated an objective response rate of 60% and a disease control rate of 96%.

The company's business model is exclusively dedicated to maximizing health benefits, with no evidence of harmful products. However, the company currently cannot consider compassionate use requests for its investigational products due to supply constraints as of January 2026, limiting access for patients in urgent need. TPI 287 has Orphan Drug Designation, granting 7 years of market exclusivity in the U.S., which can impact price accessibility. The company's Code of Business Conduct and Ethics, adopted in July 2018, outlines an ethics hotline and non-retaliation policy for reporting misconduct, but lacks specific details on risk transparency for its drug candidates. Ethical concerns related to patient consent in CNS clinical trials, particularly for Alzheimer's and Schizophrenia patients, are noted in the industry context. The company's evaluation of TPI 287 for neuroblastoma and medulloblastoma, which primarily affect children, indicates some reach to vulnerable populations. The company's Code of Business Conduct and Ethics also outlines efforts to maintain a workplace free of discrimination and harassment, and to provide a safe working environment.

Fair Money & Economic Opportunity

CNS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for brain and central nervous system cancers. The provided articles confirm that the company does not offer lending, deposit, or other financial services to consumers.

Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to its business model, as it does not engage in activities that lend, insure, move, or store money for consumers.

Fair Pay & Worker Respect

No specific, concrete data points were found in the provided articles to assess CNS Pharmaceuticals, Inc. against the defined KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, and health insurance coverage was either absent or not in a quantifiable format that aligns with the rubric's thresholds.

While policies on ethics, non-discrimination, and safety are mentioned, these do not constitute measurable performance data for the KPIs. The mention of disputed claims under the Fair Labor Standards Act in a separation agreement is not evidence of a substantiated labor law violation.

Honest & Fair Business

CNS Pharmaceuticals maintains an Ethics Hot Line for anonymous reporting of ethics violations and has a policy against retaliation for good faith reporting.

Reports of violations are stated to be promptly investigated and remedied, but there is no explicit evidence of independent investigation processes. The company's Code of Business Conduct and Ethics, adopted in July 2018, outlines policies to prevent conflicts of interest, including a $500 gift pre-approval threshold and a less than 1% ownership threshold for publicly traded companies. Directors are required to notify the CFO and Audit Committee Chairman of actual or potential conflicts and recuse themselves from related decisions. The policy covers key operations with annual acknowledgment requirements, but specific details on training frequency, effectiveness metrics, or customization for high-risk areas are not provided.

Kind to Animals

CNS Pharmaceuticals, Inc. conducts pre-clinical studies on animals to assess drug safety, as evidenced by previous pre-clinical tests on animal models.

The FDA Modernization Act 2.0, signed in December 2022, allows the FDA to consider non-animal methods during the drug approval process and removed the mandatory animal testing requirement for human drug trials, though discretion is retained. The FDA has also announced plans to phase out animal testing requirements for monoclonal antibodies and other drugs, aiming for animal research to be the exception rather than the norm for preclinical safety and toxicity testing within 3-5 years. The company's specific policy on animal testing is not detailed beyond the fact that it conducts such studies, and there is no information on the volume of animals used or investment in animal-free technologies. No data is available for other animal welfare KPIs.

Planet-Friendly Business

No specific, concrete data points were found in the provided articles regarding CNS Pharmaceuticals, Inc.'s performance across any of the Planet-Friendly Business KPIs.

The available information indicates that sustainability data for CNSP.US is currently unavailable.

Respect for Cultures & Communities

The provided articles focus exclusively on CNS Pharmaceuticals' clinical trials for Berubicin, including regulatory approvals in France, patient enrollment figures, and trial site locations across various countries.

There is no information or data within these articles pertaining to the company's engagement with local or indigenous community groups, cultural impact assessments, community investments, local employment, grievance mechanisms, or any other metrics related to the 'Respect for Cultures & Communities' value. Consequently, no KPIs can be scored based on the evidence provided.

Zero Waste & Sustainable Products

No sustainability data is available for CNSP.US in the provided articles.

explicitly states that sustainability data is currently not available for CNSP. All other articles discuss general industry trends, regulations, or the performance of other pharmaceutical companies (e.g., AstraZeneca, Sandoz, Teva, Neuraxpharm) and do not provide specific, attributable information for CNSP.US regarding waste and sustainable products.